Dr. Jori Fleisher, MD

Claim this profile

Rush University Medical Center

Studies Lewy Body Dementia
Studies Dementia
3 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.
Rush University Medical Center
Image of trial facility.
Rush University Medical Center Section Of Parkinson Disease And Movement Disorder

Clinical Trials Jori Fleisher, MD is currently running

Image of trial facility.

Caregiver Support

for Dementia

Lewy Body Dementia (LBD) is the second most common form of degenerative dementia, affecting at least 2.4 million US adults, and the overwhelming majority of persons living with LBD (PLBD) are cared for by family caregivers. LBD caregiver strain: 1) exceeds that of non-LBD dementia caregivers; 2) worsens caregiver physical and mental health; and 3) increases the risk of PLBD hospitalization and institutionalization. LBD progression is complicated by combined motor, cognitive, and neuropsychiatric decline, and is punctuated by falls, infections, dehydration, and neuropsychiatric symptoms leading to acute healthcare utilization. Although family caregivers are uniquely positioned to identify and manage these challenges, which may avert emergency department visits and reduce morbidity, many caregivers lack the knowledge, skills, confidence, resources, and support to do so. The study team aims to 1) quantify the impact of PERSEVERE on caregiver knowledge, attitudes, mastery, and strain; 2) identify the intervention and mentor factors determining implementation fidelity; and 3) test the effects of PERSEVERE on PLBD quality of life and healthcare utilization. This will be accomplished in an NIH Behavioral Model Stage II national, randomized, attention-controlled, 12-week trial of PERSEVERE in 502 LBD caregivers in partnership with the Lewy Body Dementia Association, Parkinson's Foundation, and LBD Caregiver Advisors. The study team will match intervention arm caregivers with a trained peer mentor who will coach them through a modular, theory-based curriculum on LBD knowledge and social support. Attention-control participants will receive weekly, curated links to educational materials. The study team will identify immediate and delayed intervention effects, including mediators of strain at 12 weeks, and caregiver strain and PLBD outcomes at nine months. Implementation fidelity and PLBD healthcare utilization will be tracked biweekly. Qualitative methods will explore the intervention- and mentor-specific factors predicting fidelity, mentee outcomes, and retention. Remote recruitment, mentoring, and community engagement strategies will maximize accessibility and inclusion of underrepresented caregiver groups. Results will illuminate the extent to which leveraging prior LBD caregivers as expert interventionists can improve current caregiver outcomes, and in turn, PLBD outcomes. These results will inform future adaptation and dissemination of this model for other conditions.
Recruiting1 award N/A

More about Jori Fleisher, MD

Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Jori Fleisher, MD has experience with
  • PERSEVERE
  • Neflamapimod
  • CT1812

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jori Fleisher, MD specialize in?
Jori Fleisher, MD focuses on Lewy Body Dementia and Dementia. In particular, much of their work with Lewy Body Dementia has involved treating patients, or patients who are undergoing treatment.
Is Jori Fleisher, MD currently recruiting for clinical trials?
Yes, Jori Fleisher, MD is currently recruiting for 1 clinical trial in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jori Fleisher, MD has studied deeply?
Yes, Jori Fleisher, MD has studied treatments such as PERSEVERE, Neflamapimod, CT1812.
What is the best way to schedule an appointment with Jori Fleisher, MD?
Apply for one of the trials that Jori Fleisher, MD is conducting.
What is the office address of Jori Fleisher, MD?
The office of Jori Fleisher, MD is located at: Rush University Medical Center, Chicago, Illinois 60612 United States. This is the address for their practice at the Rush University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.